EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
Orgenesis to acquire full ownership of Octomera & Metalmark to receive royalty & proceeds in exchange. Shift to decentralized production supported by regulators.